Use of sur2 receptor modulators
By targeting skeletal muscle cells with the SUR2 receptor modulator compound MLC1, inhibiting the KATP potassium ion channel, enhancing calcium ion response, and promoting glucose uptake, the serious side effects of existing diabetes drugs are solved, achieving a systemic hypoglycemic effect that effectively lowers blood sugar and avoids hypoglycemia.
CN118141816BActive Publication Date: 2026-07-03ZHEJIANG UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG UNIV
- Filing Date
- 2022-12-05
- Publication Date
- 2026-07-03
Smart Images
Figure CN118141816B_ABST
Abstract
The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.
Need to check novelty before this filing date? Find Prior Art